BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk Stock Rises on Positive Clinical Trial Results for Obesity Drug Successor
Novo Nordisk Stock Rises on Positive Clinical Trial Results for Obesity Drug Successor
14
1
BTCCSquare news:
Novo Nordisk shares climbed nearly 3% Tuesday following two significant announcements. The pharmaceutical giant revealed promising late-stage trial data for cagrilintide, a potential successor to its blockbuster Wegovy obesity treatment. Patients in the 68-week study lost an average 11.8% body weight compared to 2.3% for placebo groups, with minimal side effects.
Separate research presented at the European Association for the Study of Diabetes meeting showed Wegovy's active ingredient semaglutide reduces 'food noise'—a key psychological factor in obesity. The dual positive developments outpaced broader market performance, demonstrating continued investor confidence in Novo Nordisk's metabolic pipeline.
By:
